1651 related articles for article (PubMed ID: 18990230)
1. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
2. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.
Veeck J; Geisler C; Noetzel E; Alkaya S; Hartmann A; Knüchel R; Dahl E
Carcinogenesis; 2008 May; 29(5):991-8. PubMed ID: 18356147
[TBL] [Abstract][Full Text] [Related]
4. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
5. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
6. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
7. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
9. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
10. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
11. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
13. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
Bagadi SA; Prasad CP; Srivastava A; Prashad R; Gupta SD; Ralhan R
Breast Cancer Res Treat; 2007 Sep; 104(3):277-86. PubMed ID: 17115114
[TBL] [Abstract][Full Text] [Related]
14. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.
Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K
Oncogene; 2003 Oct; 22(48):7600-6. PubMed ID: 14576822
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
Shih YL; Shyu RY; Hsieh CB; Lai HC; Liu KY; Chu TY; Lin YW
Cancer; 2006 Aug; 107(3):579-90. PubMed ID: 16795071
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.
Kim M; Lee KT; Jang HR; Kim JH; Noh SM; Song KS; Cho JS; Jeong HY; Kim SY; Yoo HS; Kim YS
Mol Cancer Res; 2008 Feb; 6(2):222-30. PubMed ID: 18314483
[TBL] [Abstract][Full Text] [Related]
17. [Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer].
Dahl E; Veeck J; An H; Wiesmann F; Klopocki E; Sauter G; Kristiansen G; Hartmann A; Knüchel R
Verh Dtsch Ges Pathol; 2005; 89():169-77. PubMed ID: 18035687
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
19. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
20. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]